4.4 Article

In silico models in drug development: where we are

Journal

CURRENT OPINION IN PHARMACOLOGY
Volume 42, Issue -, Pages 111-121

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2018.08.007

Keywords

-

Funding

  1. ISCIII-FEDER [CPII16/00026]
  2. EU H2020 Programme [681002, 676559]
  3. IMI2-JU [116030, 777365]
  4. EU-H2020
  5. ISCIII
  6. FEDER
  7. MINECO [MDM-2014-0370]

Ask authors/readers for more resources

The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico approaches are demonstrating their ability to generate reliable predictions as well as new knowledge on the mode of action of drugs and the mechanisms underlying their side effects, altogether helping to reduce the costs of drug development. The aim of this review is to provide a panorama of developments in the field in the last two years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available